Cited by 41Cancer survivorship and careBone health and treatmentsManagement of metastatic bone disease

Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer

Open access
Cleeland, Charles, von Moos, Roger, Walker, Mark S., Wang, Yuanyuan, Gao, Jianqing, Chavez-MacGregor, Mariana, Liede, Alexander, Arellano, Jorge, Balakumaran, Arun, Qian, Yi·2016·Supportive Care in Cancer

Abstract

PURPOSE: Women with breast cancer frequently develop painful bone metastases. This retrospective study was designed to longitudinally characterize patterns of patient-reported symptoms among patients with breast cancer relative to the diagnosis of bone metastases. METHODS: Patient records were identified from the Oncology Services Comprehensive Electronic Records (OSCER) database which includes outpatient oncology practices across the USA. Symptom burden was assessed by Patient Care Monitor (PCM) assessments, which are administered as part of routine care in a subset of these practices. Eligible patients were women diagnosed with breast cancer (ICD-9-CM 174.xx) who developed bone metastases (ICD-9-CM 198.5) and had ≥1 PCM assessment between January 2007 and December 2012. The pre-specified endpoint was the occurrence of moderate to severe symptom burden, defined as PCM score ≥4 (0-10 scale). RESULTS: One thousand one hundred five women (median age, 61) met the eligibility criteria. Worsening of symptoms, particularly fatigue and pain, occurred in the months leading up to the diagnosis of bone metastases. After bone metastases diagnosis, the rate of increase in the proportion of patients experiencing moderate/severe symptoms slowed, but continued to climb during follow-up. Median time to moderate/severe symptoms was 0.9 month for fatigue, 1 month for pain, 2.9 months for trouble sleeping, and 7.7 months for numbness/tingling. Half of the patients received bone-targeted agents after diagnosis of bone metastases. CONCLUSIONS: Symptom burden, especially pain and fatigue, increased both before and after the diagnosis of bone metastases, highlighting the need for proactive monitoring and management of symptoms in breast cancer patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00520-016-3154-x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many advanced cancer patients have symptoms that interfere with functioning.

    “Many advanced cancer patients have symptoms that interfere with functioning.1–3”

    From Symptom experiences in advanced cancer: Relationships to acceptance and commitment therapy constructs (2021) · cites this paper as [2]

    The Discussion reports that pain and fatigue affected a majority of patients after the onset of bone metastases and notes the potential for bone destruction to cause loss of mobility. This supports substantial symptoms with a functional consequence in advanced breast cancer, but the paper does not establish the claim for advanced cancer patients generally or measure how often symptoms interfered with functioning. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cleeland, C., von Moos, R., Walker, M. S., Wang, Y., Gao, J., Chavez-MacGregor, M., Liede, A., Arellano, J., Balakumaran, A., & Qian, Y.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Vector Oncology (United States) (US)
  • IQVIA (United States) (US)
  • Amgen (United States) (US)
Corresponding author
Cleeland, Charles
Venue
Supportive Care in Cancer
Published
2016-03-29
Volume
24
Issue
8
Pages
3557-3565
ISSN
  • 0941-4355 (ISSN-L)
  • 1433-7339
OpenAlex
W2335598274
Cited by
41
References
34
Citations by year
2025: 5 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 8 · 2020: 4 · 2019: 9 · 2018: 1 · 2017: 2
FWCI
2.16
Type
journal article
Language
en
Open access
Locations
  • Supportive Care in Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Amgen Inc
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Surgery › Management of metastatic bone disease
Keywords
breast cancer, bone metastasis, symptom burden, fatigue, pain, sleep disorders, numbness and tingling, patient-reported symptoms, symptom onset timing, bone-targeted therapy, symptom monitoring
MeSH terms
Patient Reported Outcome Measures, Aged, Bone Neoplasms, Breast Neoplasms, Female, Humans, Middle Aged, Retrospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review